Minneapolis, MN Clinical Trials Report — June 2026

For Minneapolis residents interested in contributing to medical research, June 2026 presents both urgent opportunities and exciting new avenues for participation. With 55 clinical trials slated to conclude enrollment within the next 90 days, prompt action is essential for those looking to join studies before their deadlines.

Among these rapidly closing trials, 9 are actively seeking healthy volunteers, offering a chance to contribute to medical advancements without requiring a specific health condition. This makes June a critical month for individuals considering clinical trial participation in Minneapolis.

Impending Deadlines for Key Health Areas

Patients managing specific health conditions also have limited time to join certain research studies. Trials focused on various conditions are nearing their enrollment close dates. Conditions with trials closing soon include:

• Ovarian cancer (3 trials)
• Aortic insufficiency (2 trials)
• Endometrial cancer (2 trials)
• Traumatic brain injury (2 trials)
• Aortic valve insufficiency (2 trials)
• Aortic regurgitation (2 trials)
• Chronic pain (2 trials)
• Amputation (1 trial)
• Alcohol use disorder (1 trial)
• Acute pancreatitis (1 trial)

New Research Horizons in Minneapolis

This month, Minneapolis saw the opening of 10 new clinical trials, a decrease from the 14 trials that launched in May 2026. Despite this slight dip, the city continues to host a robust research environment with a total of 883 actively recruiting clinical trials across 259 research facilities.

June brings several high-profile new trials to Minneapolis, including significant Phase 3 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• Kallyope Inc. is sponsoring a notable Phase 3 study, NCT07645924, "A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine." This double-blind, randomized, multicenter trial aims for 1,800 participants to evaluate the efficacy, safety, and tolerability of elismetrep compared with placebo in the acute treatment of migraine.
• Another study from Kallyope Inc., NCT07674654, is "A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine." This Phase 3 study seeks 1,000 participants to evaluate the long-term safety and tolerability of intermittent use of elismetrep for acute migraine attacks.
• Pfizer is leading NCT07660198, "Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents." This Phase 3 trial aims for 1,200 participants to assess the safety and immune response of a new pneumococcal vaccine in children compared to an existing vaccine.
• Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, is sponsoring NCT07654374, "A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)." This Phase 3, randomized, double-blind, placebo-controlled study will evaluate the long-term efficacy, safety, and tolerability of aleniglipron in 1,100 participants over 76 weeks.
• RTI International is behind NCT07625579, "Collaboration for Down Syndrome Progress (CDP)." This long-term study aims to follow 1,400 people with Down syndrome of all ages to better understand their health, development, and everyday experiences.
• AngioInsight is sponsoring NCT07676097, "Simultaneous Measurement of EpicArdial and Microvascular ResisTance Via Angiographic FLOW Study." This observational multicenter study involves 620 patients to establish the diagnostic performance of the AngioAI+ System for estimating fractional flow reserve and detecting coronary microvascular disease.

New trials this month are exploring a diverse range of conditions, including acute migraine, acute or chronic coronary artery disease, cannabis use disorder, chronic weight management, Down syndrome, and metastatic breast cancer. Drug trials account for the largest share of new studies, with 3 new drug trials, followed by 2 procedure trials, and 1 each for behavioral, biological, device, and diagnostic test studies.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are valuable opportunities to contribute to research. Of the 10 new trials launched this month, 2 are actively seeking healthy volunteers. Across Minneapolis, a total of 99 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Minneapolis's Research Powerhouses

Minneapolis is home to prominent research institutions that consistently conduct a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• University of Minnesota (280 trials)
• Abbott-Northwestern Hospital (92 trials)
• Hennepin County Medical Center (77 trials)
• University of Minnesota/Masonic Cancer Center (43 trials)
• Health Partners Inc (41 trials)
• Children's Hospitals and Clinics of Minnesota - Minneapolis (27 trials)
• Minneapolis Heart Institute Foundation (24 trials)

These institutions offer a broad spectrum of research, from comprehensive academic studies at the University of Minnesota to specialized care at facilities like Abbott-Northwestern Hospital and the Minneapolis Heart Institute Foundation.

Expanding Your Search: Nearby Minnesota Cities

While Minneapolis offers a vast array of clinical trial opportunities, individuals may also find options in nearby communities within Minnesota. Cities with active trials include Rochester (12 trials), Mankato (3 trials), Duluth (1 trial), Richfield (1 trial), Saint Louis Park (1 trial), and Saint Paul (1 trial).

Participation in clinical trials is open to a diverse range of individuals. Of the 10 new trials launched this month, 8 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 3 new trials include children. Academic institutions continue to play a vital role in Minneapolis's research ecosystem, with the University of Minnesota sponsoring 3 of the new studies. Industry sponsors like Kallyope Inc. (2 trials), Pfizer (1 trial), and Gasherbrum Bio, Inc. (1 trial) are also driving significant research efforts.

As we move through June, Minneapolis's robust research community will continue to drive medical innovation, offering diverse opportunities for individuals to contribute to the future of healthcare and explore new treatment options.